IQVIA Holdings (IQV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Glenview’s sells include Cigna and HCA Continue reading...
IQVIA™ (NYSE: IQV) today announced the launch of HCP/O Engagement Management, the industry’s first end-to-end, orchestrated healthcare professional/organization (HCP/O) solution that enables the planning, management, contracting, and payment of HCP/Os globally.
It's been a pretty great week for IQVIA Holdings Inc. (NYSE:IQV) shareholders, with its shares surging 11% to US$143...
IQVIA™ (NYSE: IQV) today announced that the Walter and Eliza Hall Institute of Medical Research, a leading biomedical research organization in Australia, has selected IQVIA to manage COVID SHIELD, a Phase II/III randomized, double-blinded clinical study of preventive care for frontline healthcare workers fighting the COVID-19 pandemic.
Gartner (IT) first-quarter 2020 earnings and revenues increase year over year.
IQVIA's (IQV) first-quarter 2020 revenues increase year over year while earnings decline.
IQVIA™ (NYSE: IQV), a leader in Human Data Science, today announced the launch of its COVID Active Research Experience (CARE) Project at helpstopcovid19.com. The IQVIA CARE Project is an opt-in registry available to anyone – to advance understanding of COVID-19 through shared information about disease prevalence, symptom progression, and treatment outcomes.
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]
IQVIA (IQV) delivered earnings and revenue surprises of 1.35% and 1.38%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
IQVIA Reports First-Quarter 2020 Results; Issues Second-Quarter 2020 Guidance and Updates Full-Year 2020 Guidance
IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry, has joined the ACCORD-2 collaboration, which will fast-track development of new treatments for COVID-19. IQVIA will provide a single research platform across the United Kingdom to facilitate multiple clinical trials regardless of sponsor. This strategic alliance will examine the effectiveness of repurposed medicines, potential new drugs, and unlicensed therapies for treating COVID-19 patients.
Envestnet's (ENV) first- quarter 2020 earnings and revenues increase year over year.
Here's a sneak peek of how four business service stocks are placed prior to the respective earnings releases on Apr 28.
IQVIA™ (NYSE: IQV), a leader in Human Data Science, today announced its new technology-enabled COVID-19 Trial Matching Tool at c19trials.com, which is one of the world’s first online platforms that matches individuals with specific COVID-19 studies to accelerate clinical research projects.
IQVIA's (IQV) first-quarter 2020 revenues are likely to have benefited from strength across Research & Development Solutions, Technology & Analytics Solutions and Contract Sales & Medical Solutions.
Shares of IQVIA Holdings (NYSE:IQV) rose 1.3% after the company reported Q1 results.Quarterly Results Earnings per share decreased 1.96% over the past year to $1.50, which beat the estimate of $1.48.Revenue of $2,754,000,000 up by 2.61% from the same period last year, which beat the estimate of $2,720,000,000.Guidance Q2 EPS expected to be between $1.00 and $1.14.Q2 revenue expected to be between $2,365,000,000 and $2,440,000,000.Conference Call Details Date: Apr 28, 2020View more earnings on IQVTime: 10:05 AM ETWebcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Fir.iqvia.com%2Fevents-and-presentations%2Fdefault.aspx&eventid=2160215&sessionid=1&key=F113A19EF878954541CB973E5F79F55A®Tag=&sourcepage=registerTechnicals 52-week high: $169.14Company's 52-week low was at $81.79Price action over last quarter: down 19.23%Company Overview IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The CRO segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The legacy IMS business provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers.See more from Benzinga * Sirius XM Holdings: Q1 Earnings Insights * TE Connectivity: Q2 Earnings Insights * Recap: Cummins Q1 Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Finding oversold stocks in a crisis-driven market isn’t easy. Arm yourself with these criteria.
With me on the call today are Ari Bousbib, Chairman and Chief Executive Officer; Michael McDonnell, Executive Vice President and Chief Financial Officer; Eric Sherbet, Executive Vice President and General Counsel; Nick Childs, Senior Vice President, Financial Planning and Analysis; and Jen Halchak, Senior Director, Investor Relations. Today, we will be referencing a presentation that will be visible during this call for those of you on our webcast.
Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]